Trial Profile
Study on Safety and Efficacy of the Recombinant Factor VIII of Saman daroo 8 Pharmaceutical Company (Safacto) in Comparing with Recombinant Factor VIII of Pfizer Pharmaceutical Company (Xyntha) in Patients with Sever Hemophilia A,Exposing to Factor VIII for More Than 50 Days
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2018
Price :
$35
*
At a glance
- Drugs Recombinant-factor-VIII-Saman-Daroo-8 (Primary) ; Moroctocog alfa
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors Saman daroo 8
- 06 Mar 2018 New trial record